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Abstract
Objective
Environmental factors driving the development of type 1 diabetes (T1D) are still largely
unknown. Both animal and human studies have shown an association between altered fecal
microbiota composition, impaired production of short-chain fatty acids (SCFA) and T1D
onset. However, observational evidence on SCFA and fecal and oral microbiota in adults
with longstanding T1D vs healthy controls (HC) is lacking.
Research design and methods
We included 53 T1D patients without complications or medication and 50 HC matched for
age, sex and BMI. Oral and fecal microbiota, fecal and plasma SCFA levels, markers of
intestinal inflammation (fecal IgA and calprotectin) and markers of low-grade systemic
inflammation were measured.
Results
Oral microbiota were markedly different in T1D (eg abundance of Streptococci) compared
to HC. Fecal analysis showed decreased butyrate producing species in T1D and less
butyryl-CoA transferase genes. Also, plasma levels of acetate and propionate were lower in
T1D, with similar fecal SCFA. Finally, fecal strains Christensenella and Subdoligranulum
correlated with glycemic control, inflammatory parameters and SCFA.
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Conclusions
We conclude that T1D patients harbor a different amount of intestinal SCFA (butyrate) pro-
ducers and different plasma acetate and propionate levels. Future research should disen-
tangle cause and effect and whether supplementation of SCFA-producing bacteria or SCFA
alone can have disease-modifying effects in T1D.
Introduction
Type 1 Diabetes (T1D) is the second most frequent autoimmune disease in childhood and its
incidence has tripled in the last thirty years. Notwithstanding decades of intensive research in
animals, the environmental factors driving T1D are still unknown and therapeutic strategies
have invariably failed to halt disease progression. As the increased T1D incidence is primarily
observed in subjects who are not genetically predisposed, environmental factors including
altered diet[1], infections with concomitant antibiotic use[2] as well as mode of birth[3], have
been suggested to play a role. As autoimmune beta cell inflammation is one of the hallmarks of
T1D, this insulitis may originate from an innate immune response to intestinal pathogens[4].
Accordingly, an increased amount of pathogenic bacterial species has been observed in fecal
samples of T1D patients around time of diagnosis[5] and an altered composition of the fecal
microbiota composition was observed in adolescent T1D patients[5]. Interestingly, this altered
fecal microbiota is already present before the clinical onset of T1D[6] and is related to islet
autoantibodies[6]. Moreover, a decrease in fecal short-chain fatty acid (SCFA) producing bac-
teria was observed in small studies of T1D subjects[7], while dietary acetate and butyrate sup-
plementation elicits favorable immunological effects and protection from T1D in NOD mice
[8].
Most human studies have been performed in children and adolescents with T1D[5,7],
whereas patients with longstanding T1D have only been studied in a small group[9] without
taking several confounding factors including gender and diet into account. More recently, oral
microbiota have been implicated in development of type 2 diabetes[10] and liver disease[11],
but these have never been studied in T1D. We therefore set out to study both fecal and oral
microbiota composition, as well as SCFA metabolism in a large matched case-control study of
T1D patients and control subjects.
Methods
Recruitment and study visit
Outpatient clinics of six medical centers in the Amsterdam region in the Netherlands were
screened for eligible T1D patients. From a total amount of 854 T1D subjects, 82 eligible sub-
jects were selected by their treating physician based on our inclusion criteria and approached
for participation. The large majority of noneligible patients were excluded due to cormorbidity
affecting glucose control or gut microbiota (eg recent antibiotic use or use of proton pump
inhibitors) or because end organ damage was present. In a few cases (N = 5) other reasons
were given (e.g. expected nonadherence, mental performance, language barrier). Finally, from
82 eligible patients, 53 subjects agreed to participate. In total, 83 control subjects were recruited
by advertisement of which 50 were eligible for participation. Subjects were matched for age,
sex and BMI. Written informed consent was obtained from all subjects. The study was con-
ducted at the Academic Medical Center (Amsterdam) in the period between November 2013
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and April 2014, in accordance with the Declaration of Helsinki (updated version 2013). The
study was approved by the ethics review board of the Academic Medical Center.
Inclusion criteria for T1D patients were of Western European descent, age 18–65 years,
normal BMI (18.5–25 kg/m2), and a Western dietary pattern. Exclusion criteria were known
determinants of altered microbiota composition including medication use including statins
and proton pump inhibitors, use of antibiotics three months prior to inclusion, use of probi-
otic-containing food, unusual dietary habits (e.g. vegan diet) and medical conditions believed
to affect glucose metabolism or gut microbiota (e.g. cholecystectomy, celiac disease and irrita-
ble bowel syndrome)[12]. As we aimed to investigate uncomplicated longstanding T1D
patients, we excluded poorly regulated subjects (HbA1c > 10% or 86 mmol/mol) as well as
subjects with microvascular complications of T1D (nephropathy, neuropathy or retinopathy).
Both T1D and controls were allowed to continue their diet and were asked to fill out an
online nutritional diary (www.voedingscentrum.nl) for the duration of one week before the
study visit to monitor caloric intake including the amount of dietary carbohydrates, fat, pro-
teins and fibers. Anthropometric and physiological measurements including blood pressure,
length, weight, hip and waist circumference) were recorded. After an overnight fast, blood was
drawn and fresh morning feces were collected. Participants were asked to refrain from tooth
brushing in the twelve hours before collection of oral swabs, that were taken taken between the
upper lip and the front row of teeth for oral microbiota analysis as previously published[10].
All samples were stored at -80˚C until analyzed.
Plasma samples
Total cholesterol, low density lipoprotein cholesterol (LDLc), high density lipoprotein choles-
terol (HDLc) and triglycerides (TG) were measured by using commercially available enzy-
matic assays (Randox, USA and Daiichi, Japan). All analyses were performed using a Cobas
Mira autoanalyzer (Horiba, France). C-Reactive Protein (CRP, Roche Diagnostics), LPS-bind-
ing protein (Human LBP ELISA kit, Hycult biotech, catalog no. HK315), fecal calprotectin
(Buhlmann), and fecal IgA (human IgA ELISA Kit, eBioscience) were determined. Plasma
SCFA were determined using liquid chromatography-mass spectrometry according to van
Eijk et al[13], with minor modifications.
Fecal samples
Fecal SCFA were measured using high-performance liquid chromatography with UV detec-
tion as previously published by De Baere et al.[14]. DNA was extracted from non-thawed fecal
samples using a bead-beating protocol and analysis of microbiota diversity and composition
was performed by Illumina Miseq sequencing (Illumina, San Diego, CA, USA) of 16S rRNA
genes from extracted DNA with primers 27F-DegS and 338R[15]. The average number of
reads was 12158 with a lower limit of 1187. Sequencing data were analyzed using NG-tax[16]
and for follow up analyses the QIIME software package (available at http://qiime.sourceforge.
net/), the Canoco 5 software package (Biometris, Wageningen, the Netherlands) and R-studio
were used. Several fecal and saliva samples were not collected, properly stored or lost during
the DNA extraction or processing steps. Hence, fecal microbiota were assessed in 45 T1D vs
35 controls. Oral microbiota were assessed in 51 T1D vs 42 controls. Fecal SCFA were assessed
in 43 T1D vs 47 controls. All other parameters including plasma SCFA were assessed in all
participants.
Butyrate production capacity was assessed by qPCR targeting the Butyryl-coenzyme A
(CoA)-CoA transferase (ButCoA) gene using 25 ng of template DNA and 0.5μM primer con-
centration in each reaction as previously described[17]. qPCR amplifications were performed
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in triplicate using MX3005P Real-Time PCR System (Stratagene, La Jolla, CA, USA) in a vol-
ume of 25 μl. Each reaction was amplified by using 5 μl of HOT FIREPol EvaGreen qPCR Mix
Plus, no ROX (Solis BioDyne, Tartu, Estonia). The number of copies of the butyryl-CoA trans-
ferase-acetate-CoA transferase gene in feces was measured and expressed as a percentage of
the total amount of 16S rRNA gene copies, which allows to make an estimation of the abun-
dance of all butyrate producing bacteria.
Statistics
To test significance between group differences, unpaired Student t-test or the Mann-Whitney
test were used, depending on the distribution of the data. Accordingly, data are expressed as
mean ± the standard deviation or as median with interquartile range. For correlation analyses,
Spearman’s Rank test was used (as all parameters shown had non-normal distribution). A p-
value < 0.05 was considered significant. Differences in fecal and oral microbiota composition
between groups (beta diversity) were assessed visually using RDA-plots and per species with
Wilcoxon’s signed rank test. A false-discovery-rate corrected p-value (q-value <0.05) was con-
sidered statistically significant; ‘qvalues’ package in R was used for testing. For testing alpha
diversity (the species diversity within an individual or mean individual diversity within a
group) we used Shannon’s diversity index. Intestinal bacterial species discriminating between
controls and the T1D group were selected using the elastic net algorithm[18,19]. A randomiza-
tion test was conducted to evaluate the statistical validity of the results obtained via elastic
net algorithm. We followed the procedure where the outcome variable (e.g T1D vs. control)
was randomly reshuffled while the corresponding microbial profiles were kept intact. This was
repeated up to 100 times and Receiver-Operating-Characteristics Area-Under-Curve (ROC
AUC) scores were computed each time. The performance measure used for a binary classifica-
tion task is an ROC AUC. The ROC can be understood as a plot of the probability of correctly
classifying T1D vs. control subjects. Cross-validation within the dataset was accomplished by
randomly hiding 20% of the subjects from the model and evaluating the prediction quality on
that group. The ROC AUC score measures the predictive accuracy of the classification model
with 0.5 AUC corresponding to a random result. A significance value of 0.05 was defined and
the true AUC of the original dataset was compared with this value. All statistical analyses were
performed using Numerical Python, R, and MATLAB.
Results
Baseline characteristics of both study groups are depicted in Table 1. T1D and matched con-
trols did not differ in age, sex or BMI. Total caloric intake (proteins, fat or carbohydrate) was
not significantly different between groups, in spite of a trend towards higher fiber intake
observed in T1D subjects (Fig 1A). Although fecal SCFA levels were not different between
both groups (Table 1), in fasting plasma of T1D we observed lower acetate and propionate lev-
els (Fig 1B–1D). While plasma acetate and butyrate were significantly correlated in T1D (r =
+0.357, p = 0.009), a negative correlation between plasma acetate and propionate was observed
in the controls (r = -0.432, p = 0.002) (S1 Fig). Markers of chronic inflammation (e.g. LBP and
CRP) as well as fecal calprotectin and fecal IgA were not significantly different between the
groups (see Table 1). However, a correlation between fecal calprotectin and plasma LPS-bind-
ing protein (LBP) levels (r = +0.23, p =<0.05), and plasma LBP and CRP (r = 0.6, p<0.001)
was noted in both groups. Furthermore, in the T1D group HbA1c was directly correlated to
plasma LBP (r = +0.3, p<0.05), whereas fecal IgA correlated strongly with fecal butyrate in the
T1D group (r = +0.65, p<0.001). Finally, although age range-dependent sex differences have
been reported in relation to the incidence of type 1 diabetes[20,21], no difference was found in
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inflammatory parameters or short-chain fatty acids between males and females in either
group.
Fecal and oral microbiota composition
A difference in fecal microbiota beta diversity was seen as depicted by RDA plot (Fig 2A),
while there was no significant in alpha diversity (Shannon’s diversity index) in T1D (N = 45)
versus controls (N = 35). Regarding fecal microbiota, on the level of individual taxa only one
genus and one family were significantly different (p<0.05) between the groups; Christensenella
(p = 0.015) and Rhodospirillales (p = 0.009) whereas the adjusted q-values did not remain sig-
nificant; When applying the elastic net algorithm to identify intestinal bacterial species most
discriminating as a group between T1D and controls, we could identify several fecal and oral
species with high sensitivity (AUC 0.88) that were predictive to belong to either the T1D or the
HC group (Table 2 and Fig 3A and 3B). In feces, Christensenella associated with T1D and cor-
related negatively with fecal acetate (Spearman r = -0.416, p<0.05), whereas Subdoligranulum
correlated significantly with plasma markers of endotoxemia (LBP, r = 0.519, p<0.001) and
inflammation (CRP, r = 0.362, p<0.05, S2A Fig) in T1D. Also, butyryl-CoA:acetate-CoA-
transferase gene ratio was significantly decreased in T1D fecal samples (3.1± 1.1% vs 5.8±0.6%,
p = 0.03), which is in line with our findings of lower Roseburia, a known butyrate producer in
T1D (Table 2 and Fig 3A and 3B). Finally, these key fecal microbiota species from the elastic
Table 1. Baseline characteristics.
Baseline characteristics T1D (n = 53) HC (n = 50) P value
Age (years) 35 ± 9 36 ± 13 NS
Sex (% male) 53 52 NS
BMI (kg/m2) 22.8 ± 1.9 22.2 ± 2.0 NS
Diabetes duration (years) 9 [5–16]
Insulin use (IU/day) 44 ± 16
HbA1c (mmol/mol,%) 59, 7.5 [52–64, 6.9–8.0]
C-reactive protein (mg/l) 0.6 [0.3–1.2] 0.5 [0.3–0.8] NS
Leukocytes (109/l) 5.3 [4.6–6.1] 5.4 [4.7–6.5] NS
LPS-binding protein (μg/ml) 13.7 [12.3–17.8] 15.0 [12.2–19.8] NS
Fecal calprotectin (μg/g) 22.0 [1–53] 9.5 [1.0–29.0] NS
Fecal IgA (ng/ml) 1154 [676–1989] 856 [382–2116] NS
Fecal acetate (mmol/g) 36.4 [23.3–47.8] 37.2 [22.6–44.9] NS
Fecal propionate (mmol/g) 223 [150–329] 227 [149–397] NS
Fecal butyrate (mmol/g) 66.2 [42.4–118] 76.3 [53.3–113.9] NS
Total fecal SCFA (mmol/g) 341 [250–507] 348 [240–534] NS
Plasma acetate (μmol/l) 29.7 [17.4–54.3] 44.4 [20.9-69-2] 0.034
Plasma propionate (μmol/l) 0.85 [0.53–1.41] 1.12 [0.75–1.48] 0.032
Plasma butyrate(μmol/l) 0.79 [0.60–1.11] 0.84 [0.61–1.05] NS
Total calories (kcal/day) 1998 [1712–2388] 1956 [1725–2507] NS
Protein intake (g/day) 81 [69–92] 74 [64–88] NS
Carbohydrate intake (g/day) 212 [164–252] 224 [167–275] NS
Fat intake (g/day) 79 [69–101] 77 [66–96] NS
Fiber intake (g/day) 23.0 [18.1–29.2] 20.6 [16.4–24.7] 0.060
Group characteristics expressed as mean ± SD or median [IQR] with p-value using independent T-test for parametric and Mann-Whitney test for non-
parametric data.
https://doi.org/10.1371/journal.pone.0188475.t001
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net analyses were correlated with clinical and metabolic parameters, which is summarized in
S2A and S2B Fig.
With respect to oral microbiota, beta diversity also differed between the groups (Fig 2B).
T1D subjects were characterized by a significantly higher abundance of taxa belonging to the
phyla Actinobacteria and Firmicutes, including Streptococcus spp., Actinomyces spp. and
Rothia spp (q values <0.05) (see Table 3 and Fig 4A and 4B). In contrast, Bacteroidetes and
Proteobacteria phyla were significantly increased in controls including Pasteurellaceae
(q = 0.032). In contrast with fecal microbiota, we found no significant correlations between
oral microbiota and glycemic control, inflammatory parameters or short-chain fatty acids.
Discussion
Recent studies have linked altered fecal microbiota composition to the recent rise in many
immunological disorders including T1D. Indeed, the intestinal microbiota composition seems
to differ between new onset adolescent T1D subjects and controls[5]. In this regard, antibiotic
administration has been associated with T1D incidence both in mice[22]and humans[23]. In
patients with longstanding T1D, we now report that oral as well as fecal microbiota are altered
compared to healthy matched controls.
While previous studies reported a decrease in alpha diversity in young adolescent T1D[5],
we only found significant changes in beta diversity in both fecal and oral microbiota in our
well-controlled longstanding T1D patients, which is in line with a previous smaller study in
longstanding T1D[9]. Moreover, on the genus level we found that fecal samples of T1D were
enriched in Christensenella and Bifidobacteria (Table 2 and Fig 3A and 3B), which suggests
that low fecal Bifidobacterium levels reported around the time of diagnosis[7] have recovered
in longstanding T1D patients. Our finding of increased abundance of Christensenella, which
has been previously linked to lower obesity risk,[24] is a novel finding in T1D. In line with
lower plasma SCFA levels, decreased fecal levels of the butyryl-CoA:acetate-CoA transferase
gene as well as SCFA producers like Roseburia, were seen in the T1D group. These findings are
Fig 1. Plasma SCFA and dietary fiber intake. The figure shows that (A) despite higher fiber intake, we (B) found decreased plasma levels of
acetate and (C) propionate and (D) similar levels of plasma butyrate in controls vs T1D subjects.
https://doi.org/10.1371/journal.pone.0188475.g001
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in line with a recent study in non-obese diabetic (NOD) mice that showed an inverse correla-
tion with key features of T1D and plasma blood SCFA concentrations, whereas diet containing
Fig 2. Fecal microbiota composition. Differences in (A) fecal and (B) oral microbiota composition as
depicted by a biplot of Redundancy Analysis (RDA axis 1 vs. axis 2) constrained by T1D or controls.
https://doi.org/10.1371/journal.pone.0188475.g002
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Table 2. Most discriminating fecal genera from elastic net analysis.
Genus mean
abund.
T1D**
In %
of T1D
mean
abund.
HC**
In %
of HC
Ratio
T1D:HC
Weight
in model
p-value* q-value*
Genus of Bacteriodales 0.0044 38 0.0011 20 4.0 0.64 0.093 0.653
Christensenella 0.0002 16 0.0000 0 Inf** 0.515 0.015 0.311
Bifidobacterium 0.0057 60 0.0022 43 2.6 0.463 0.248 0.311
Ruminococcus 0.0540 98 0.0417 89 1.3 0.345 0.464 0.320
Genus of Christensenellaceae 0.0267 89 0.0165 80 1.6 0.306 0.385 0.392
Subdoligranulum 0.0068 93 0.0282 91 0.2 -0.152 0.764 0.390
Streptococcus 0.0023 73 0.0039 77 0.6 -0.292 0.371 0.318
Barnesiella 0.0001 56 0.0040 51 0.0 -0.304 0.664 0.390
Haemophilus 0.0113 7 0.0159 17 0.7 -0.342 0.122 0.306
Roseburia 0.0000 76 0.0004 89 0 -0.401 0.348 0.318
Genus of Rhodospirillales 0.0000 0 0.0005 14 0.1 -0.585 0.009 0.193
Chloroplast 0.0044 2 0.0011 11 4.0 -0.817 0.089 0.311
Mean relative abundance, percentage of subjects harboring species and ratio of most discriminating fecal microbiota from our predictive models analysis.
Taxa are ordered by weight in the predictive model from highest positive to lowest negative.
*Taxa shown are discriminatory between cases and controls as a group and not on the individual level. Nevertheless, calculated p and q values (using
Mann-Whitney U-test and q-value package in R) are included for completeness.
**“T1D” type 1 diabetes, “HC” healthy controls, “inf” infinite.
https://doi.org/10.1371/journal.pone.0188475.t002
Fig 3. Most discriminating fecal species. Relative abundances of most discriminating fecal microbiota
resulting from our elastic net analysis for (A) T1D patients and (B) healthy controls (B).
https://doi.org/10.1371/journal.pone.0188475.g003
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SCFA boosted the number and function of regulatory T cells, enhanced gut integrity and
decreased chronic low grade inflammation[8]. In this study various in vivo and in vitro experi-
ments using transfer of T-cell subsets and labeling show that oral administration of acetate
changes the composition of B cell subsets, thereby affecting the proliferation of T-cells in the
spleen and pancreatic lymph nodes whereas infiltration of pancreatic islets was decreased,
thereby protecting from the development of autoimmune diabetes[8]. In contrast, no protec-
tive effects of propionate against T1D development were observed[8]. Nevertheless literature
on role of SCFAs in T1D or its effects on the adaptive immune system in general are scarce
and warrants further study.
Interestingly, we also found changes in bacteria in the proximal part of the intestine with
Streptococcus in the oral cavity being positively associated with T1D, whereas fecal Streptococ-
cus showed an inverse relationship (Table 2 and Fig 3A and 3B). This might be clinically rele-
vant since the immune system in the small intestine of T1D subjects seems to reacts differently
than that of healthy controls to Streptococcus which are abundant throughout the entire ali-
mentary tract[15]. In line with our data, Subdoligranulum has been reported to be associated
with poorer metabolic control and chronic inflammation[25]. Besides altered function of the
adaptive (T-cell) immune system[26], T1D has been linked to an altered innate immune func-
tion[27] including changes in Toll-like receptor signaling[28] and increased bacterial translo-
cation[29]. In line, a recent study showed that gut-derived bacterial lipopolysaccharide from
Bacteroides may preclude proper immune system regulation[30]. Furthermore, our observed
correlation between fecal IgA and fecal butyrate levels suggests that SCFA play a role in differ-
ential IgA targeting of specific intestinal bacteria in (de novo) T1D (e.g. Bacteroides spp)[31].
While differences in altered butyrate production between T1D and controls have been
reported, fecal SCFA levels did not differ between groups. However, SCFA levels poorly reflect
biologically active SCFA levels, as only 5–10% is found in feces and plasma[32], and the major-
ity of microbiota-derived butyrate is consumed by the intestinal epithelium. Moreover after
SCFAs have been formed in the intestine, they are subjected to a high intestinal inter-conver-
sion due to microbial cross-feeding and the differential pathways via which these SCFA are
Table 3. Most discriminating oral genera from elastic net analysis.
Genus Mean
abund.
T1D**
In %
of T1D
Mean
abund.
HC**
In %
of HC
Ratio
T1D:HC
Weight
in model
p-value* q-value*
Derxia 0.0005 14 0.0000 14 16.2 0.133 0.064 0.116
Pasteurella 0.0002 8 0.0000 8 Inf** 0.126 0.079 0.116
Streptococcus 0.5337 100 0.4306 100 1.2 0.106 0.007 0.035
Rothia 0.0027 39 0.0009 39 3.1 0.088 0.006 0.035
Actinomyces 0.0044 33 0.0002 33 18.5 0.069 0.007 0.035
Genus of Pasteurellaceae 0.0029 61 0.0035 61 0.8 -0.051 0.28 0.146
Bergeyella 0.0010 27 0.0017 27 0.6 -0.058 0.117 0.130
Actinobacillus 0.0270 53 0.0530 53 0.5 -0.091 0.1 0.130
Campylobacter 0.0011 20 0.0032 20 0.3 -0.144 0.615 0.203
Porphyromonas 0.0225 78 0.0481 78 0.5 -0.157 0.072 0.116
Mean relative abundance, percentage of subjects harboring species and ratio of most discriminating oral microbiota from our predictive models analysis.
Taxa are ordered by weight in the predictive model from highest positive to lowest negative.
*Taxa shown are discriminatory between cases and controls as a group and not on the individual level. Nevertheless, calculated p and q values (using
Mann-Whitney U-test and q-value package in R) are included for completeness.
**“T1D” type 1 diabetes, “HC” healthy controls, “inf” infinite.
https://doi.org/10.1371/journal.pone.0188475.t003
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further metabolized have been only partly unveiled24. Nevertheless, the decreased amounts of
plasma acetate and propionate in T1D might be of interest, since propionate has been linked
to endogenous hepatic glucose production[33], which was previously reported to be higher in
T1D[34]. The discordant correlations between propionate and acetate in both T1D and con-
trols (S2 Fig) may thus point towards relevant differences in acetate metabolism. In this regard
it is noteworthy that acetate can protect from the development of anti-islet cell autoantibodies
[35], while serum acetate directly influences CD8+ memory T cell function[36].
Finally, it has previously been recognized that altered oral health is observed in T1D and is
invariably related to glucose regulation[37]. In contrast to fecal microbiota, we observed a
much stronger oral microbiota signature (including Streptococcus) in T1D subjects. Interest-
ingly, pancreatic duct infusion with Streptococci is linked to CD43+ accumulation and beta cell
inflammation in animals[4]. Since oral microbiota are claimed to highly resemble the small
Fig 4. Most discriminating oral species. Relative abundances of most discriminating oral microbiota
resulting from our elastic net analysis for (A) T1D patients and (B) healthy controls (B). Please note that the y-
axes differ between figures and that Streptococcus abundance was relatively very large (0.53 in T1D and 0.43
in healthy controls) and did not fit in the figure.
https://doi.org/10.1371/journal.pone.0188475.g004
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intestinal microbiome[15], it is tempting to speculate that these oral bacterial strains may
indeed contribute to T1D development.
Our study was performed in T1D patients without complications. Since this comprises only
one third of all T1D subjects, it precludes direct extrapolation of our findings to other sub-
groups of T1D patients. Another caveat involves the notion that diet can influence gut[38] and
oral microbiota composition. In spite of close monitoring of caloric intake in both groups, a
trend towards different fiber intake in T1D was noted that might introduce some bias. Finally,
there might be a reciprocal relation between hyperglycemia and altered microbiota composi-
tion[39]. However, our population had good glycemic control without diabetes complications
and no correlations were seen between significantly different oral or fecal taxa and HbA1c.
Finally, as we did not perform HLA typing, we cannot provide data on the potential relation
between HLA type and intestinal microbiota composition In T1D.
In conclusion, our study reveals that intestinal microbiota are different in well-controlled
subjects with longstanding T1D compared to matched healthy controls. Moreover, correla-
tions between markers of gut inflammation, endotoxemia and glycemic control in relation to
SCFA were observed in T1D subjects suggesting potential pathophysiological links in T1D
pathogenesis. In this respect, we are currently executing a fecal microbiota transplantation
study in new onset T1D which may provide more insight into potential causality of (small)
intestinal microbiota and their metabolites[40] in this autoimmune disease. Especially the
observed differences in oral microbiota are of interest in view of recent human studies suggest-
ing a link between oral microbiota and microbiota in the small intestine, which is believed to
be the culprit site in T1D development[41].
Supporting information
S1 Fig. SCFA correlations. The figure shows correlations between plasma and fecal SCFA’s in
T1D subjects and healthy controls. Of note, acetate is differentially correlated to propionate
and butyrate in T1D vs healthy controls.  <0.05, <0.01.
(PPTX)
S2 Fig. Correlations of key microbes with other parameters. Correlations of key microbes
are depicted with clinical and inflammatory parameters and SCFA for T1D (A) and healthy
controls (B). (+) indicates increased abundance in T1D, (-) indicates reduced abundance in
T1D. Taxa Erysipelotrichaceae and Subdoligranulum were not significantly different between
groups, but correlated significantly with a large number of clinical parameters.
(PDF)
S1 Database File. Excel database file containing raw data.
(CSV)
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